Bimzelx market forecast points to faster growth in biologics

The Business Research Company says the global Bimzelx market is set for notable expansion through 2035 as biologic adoption, personalized medicine and broader use in inflammatory diseases support demand. North America leads now, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The Bimzelx market is tied to the wider shift toward biologic therapies for chronic inflammatory diseases. - Growth in personalized medicine and healthcare infrastructure is widening access to advanced treatment options. - Expanding use beyond psoriasis could increase the drug’s commercial reach across autoimmune care.

What happened: - The Business Research Company published its Bimzelx Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 2, 2026. - The report says the market is gaining attention as biologic therapies reshape treatment for chronic inflammatory conditions. - The report projects notable development in the market through 2035. - The report says North America held the largest global market share in 2025. - The report says Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Bimzelx is a monoclonal antibody used in adults with moderate to severe plaque psoriasis who need systemic therapy or phototherapy. - The drug inhibits interleukin-17A and interleukin-17F, which are key drivers of inflammation in psoriasis. - Bimzelx is administered by subcutaneous injection. - The report says the market’s historical growth was driven by monoclonal antibody advances, unmet psoriasis treatment needs, recognition of IL-17’s role in inflammation, wider biologic use in dermatology and specialist-driven prescribing. - The report says future growth will be supported by broader indications beyond psoriasis, higher biologic adoption in autoimmune disease, dermatologist preference for therapies that target multiple pathways, improved reimbursement and greater patient awareness. - The report highlights dual IL-17 inhibition, high-efficacy psoriasis treatments, expansion into inflammatory conditions, long-acting injections and less frequent dosing as emerging trends. - The report links personalized medicine to demand for Bimzelx because the drug targets inflammatory pathways in a more specific way. - The report says Bimzelx may be used in chronic inflammatory diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. - The report cites the Personalized Medicine Coalition as saying the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - The report says healthcare infrastructure supports Bimzelx use through better diagnostics, treatment delivery and monitoring. - The report cites UK government support of more than $25.45 billion (£20 billion) in hospital infrastructure investments through the New Hospital Programme in May 2023. - The program aims to build 40 new hospitals in England by 2030, including facilities addressing RAAC concerns and mental health hospitals funded through broader capital investments.

Between the lines: - The market story is not just about one drug. It reflects rising demand for biologics that can deliver stronger outcomes and simpler dosing. - Better reimbursement and stronger health systems are becoming as important as clinical efficacy for market growth. - Regional momentum suggests mature markets still dominate sales, while emerging markets may provide the fastest expansion.

What's next: - The report expects broader indications and higher biologic adoption to drive the next phase of growth. - Asia-Pacific’s infrastructure spending and growing patient base could make it the main growth engine over the forecast period. - The report’s updated tools include TAM analysis, company scoring matrices, Excel dashboards, hotspot graphics and refreshed graphics and tables. - The full report is available here, and a free sample is available here.

The bottom line: - Bimzelx is positioned to benefit from the broader move toward targeted, higher-efficacy biologics as chronic inflammatory disease treatment evolves.